anti-topoisomerase IACAanti-centromereATASystemic sclerosis (SSc)systemic sclerosisSScscleroderma
…ent. Distinct autoantibodies, such as anti-centromere (ACA) and anti-topoisomerase I (ATA), are associated with different clinical phenotypes, but t…
10,506articles mentioning drugs
58,393drug mentions
9,496distinct drugs extracted
0%of mentions human-reviewed
All extracted drugs
Showing 781–840 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
RASI4bisphosphonate4Ivonescimab4VDZ4IABP4WEB4Edaravone4Fenfluramine4PEG-IFN4Tadalafil4BDP/FF/G4Eltrombopag4THC4Adagrasib4Contour4Formaldehyde4Mosunetuzumab4TDF4TP4Tralokinumab4riociguat4Mirikizumab4PDE5i4Tobramycin4leptin4ACEI4EmboTrap4Palonosetron4glargine4177Lu4AIR4Brainomix4Desmopressin4Indomethacin4NT-pro BNP4risedronate4Adiponectin4Aldesleukin4HTPs4IL-214NSBBs4angiotensin converting enzyme inhibitors4cortisol4sodium valproate4ADU-S1004CLDN18.24Clavien-Dindo4Cytisine4FFP4Glofitamab4Perineural dexamethasone4TAC4TGFβ14Talquetamab4amoxicillin-clavulanic acid4buprenorphine/naloxone4eptifibatide40.25% ropivacaine4Antithrombotics4ERA4
Articles mentioning drugs
10,506 articles · page 159 of 876mycophenolate mofetilmethotrexatecyclophosphamiderituximabfludarabineanti-thymocyte globulinDiffuse cutaneous systemic sclerosis (dcSSc)dcSSc
… AHSCT after failing standard therapies including methotrexate, mycophenolate mofetil, cyclophosphamide, and rituximab. The conditioning regimen cons…
cyclophosphamidefludarabinerese-celsystemic sclerosis (SSc)SSc-Skin-1SSc-Skin-2SSc-Skin-1Abstract
…was administered following preconditioning with fludarabine and cyclophosphamide. All non-glucocorticoid (GC) IM agents were stopped by Day -5. …
M10scleroderma
…ine content attenuating established dermal fibrosis.Conclusions M10 counteracts fibrogenic pathways in SSc skin fibroblasts and sup…
GLP-1 RAGLP-1 RAsglucagon-like peptide-1 receptor agonistIBDinflammatory bowel diseaseobesity
…s. There is a rapid, largely hidden surge in direct-to-consumer GLP-1 RA use among patients with IBD. Integrated pathways and prospectiv…
obesity medicationsobesity medicationmedicationobesitytype two diabetes
…nd evaluate coverage decisions for obesity treatment, including obesity medications.292 293healthcare professionals should add a diagnosis of overw…
afliberceptAflibercept biosimilarsneovascular age-related macular degenerationnAMD
…bercept in eyes with treatment-naïve nAMD following an on-label aflibercept treatment protocol; however, real-world extended durability rem…
PrEPHIVMinistry of HealthPrEP
… to estimate associations between discrimination and early oral PrEP discontinuation within 3 months of initiation, adjusting for co…
clobetasolVisual Analogue Scaleocular inflammationCLOSE-1CLOSE-2
…act surgeryInterventions Participants were randomised to either clobetasol or placebo four times a day for 14 days. Follow-up visits occur…
CC-99677Ankylosing SpondylitisASNCT04947579
…eristics were typical of an AS trial population. Treatment with CC-99677 was generally well-tolerated. ASAS20 and ASAS40 at week 12 were…
B/F/TAFBictegravirtenofovir alafenamideemtricitabineHIVPWH
…o or initiating their first antiretroviral treatment (ART) with B/F/TAF were included. PWH were followed up until treatment discontinua…
levosimendanWEANLESSEQ-5DNCT07105202
…length of stay. WEANLESS includes a pharmacokinetic analysis of levosimendan and its metabolites.Discussion WEANLESS is the first clinical s…